ATE377087T1 - Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors - Google Patents

Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors

Info

Publication number
ATE377087T1
ATE377087T1 AT98930594T AT98930594T ATE377087T1 AT E377087 T1 ATE377087 T1 AT E377087T1 AT 98930594 T AT98930594 T AT 98930594T AT 98930594 T AT98930594 T AT 98930594T AT E377087 T1 ATE377087 T1 AT E377087T1
Authority
AT
Austria
Prior art keywords
bovine adenovirus
producing
provision
vectors
adenovirus vector
Prior art date
Application number
AT98930594T
Other languages
English (en)
Inventor
Lorne Babiuk
Suresh Tikoo
Police Reddy
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Application granted granted Critical
Publication of ATE377087T1 publication Critical patent/ATE377087T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98930594T 1997-06-23 1998-06-23 Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors ATE377087T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88023497A 1997-06-23 1997-06-23

Publications (1)

Publication Number Publication Date
ATE377087T1 true ATE377087T1 (de) 2007-11-15

Family

ID=25375809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930594T ATE377087T1 (de) 1997-06-23 1998-06-23 Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors

Country Status (8)

Country Link
US (1) US6319716B1 (de)
EP (1) EP0998576B1 (de)
JP (4) JP4812914B2 (de)
AT (1) ATE377087T1 (de)
AU (1) AU8097698A (de)
CA (2) CA2594375C (de)
DE (1) DE69838644T2 (de)
WO (1) WO1998059063A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) * 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
DE69838644T2 (de) 1997-06-23 2009-05-14 The University Of Saskatchewan Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
EP1127151A2 (de) * 1998-11-02 2001-08-29 University of Saskatchewan Bovine zellen,die essentielle adenovirale funktionen zur verfügung stellen, für die vermehrung von rekombinanten adenoviralen vektoren
US6451319B1 (en) * 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
US6737519B1 (en) * 1999-07-30 2004-05-18 Genome Therapeutics Corporation Human genes relating to respiratory diseases and obesity
ATE429927T1 (de) 2000-02-04 2009-05-15 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
JP2003534805A (ja) * 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン 変化した親和性を有する改変ウシアデノウイルス
BR0318114B1 (pt) 2003-02-19 2014-09-02 Merial Ltd Vacinação ou imunização utilizando um regime de iniciação-reforço
US7264818B2 (en) * 2003-06-10 2007-09-04 University Of Saskatchewan BAV packaging regions and E1 transcriptional control regions
US20050032045A1 (en) * 2003-06-10 2005-02-10 Tikoo Suresh K. Chimeric adenovirus capsid proteins
WO2017221075A1 (en) * 2016-06-24 2017-12-28 University Of Saskatchewan pV-DELETED BOVINE ADENOVIRUS

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962424A (en) 1974-01-31 1976-06-08 Recherche Et Industrie Therapeutiques (R.I.T.) Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
WO1986006409A1 (en) 1985-05-01 1986-11-06 Genetics Institute, Inc. High level amplification and expression of exogenous dna
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
FR2642767B1 (fr) 1989-01-19 1993-10-01 Transgene Sa Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation
DE69027695T2 (de) 1989-03-24 1997-02-20 Wistar Inst Rekombinanter Cytomegalovirus-Impfstoff
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
FR2657880A1 (fr) 1990-02-02 1991-08-09 Fondation Nale Transfusion San Production de proteines recombinantes a partir de cellules lymphoblastouides humaines et d'heteromyelomes.
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5820868A (en) * 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
NZ300387A (en) * 1994-12-12 2001-07-27 Genetic Therapy Inc Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
DE19525900C1 (de) * 1995-07-15 1996-12-12 Max Planck Gesellschaft Leberspezifischer Adenovirus-Expressionsvektor
EP0866721A4 (de) 1995-12-08 2003-06-04 Univ Alabama Birmingham Res Fo Adenovirale zielvektoren
DE69838644T2 (de) 1997-06-23 2009-05-14 The University Of Saskatchewan Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses

Also Published As

Publication number Publication date
JP2006340731A (ja) 2006-12-21
DE69838644T2 (de) 2009-05-14
CA2294649A1 (en) 1998-12-30
US6319716B1 (en) 2001-11-20
WO1998059063A2 (en) 1998-12-30
JP5506736B2 (ja) 2014-05-28
AU8097698A (en) 1999-01-04
CA2594375C (en) 2015-12-22
WO1998059063A3 (en) 1999-07-29
CA2594375A1 (en) 1998-12-30
JP2011167204A (ja) 2011-09-01
EP0998576B1 (de) 2007-10-31
JP4812914B2 (ja) 2011-11-09
JP2002508661A (ja) 2002-03-19
EP0998576A2 (de) 2000-05-10
CA2294649C (en) 2007-09-25
JP2008054680A (ja) 2008-03-13
DE69838644D1 (de) 2007-12-13

Similar Documents

Publication Publication Date Title
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
ATE377087T1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
WO2001087978A3 (en) Human abc transporter and its use
WO2002006302A3 (en) 16816 and 16839, novel human phospholipase c molecules and uses therefor
WO2002032939A3 (en) Secreted proteins and their uses
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
WO2002026801A3 (en) Secreted proteins and their uses
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
ATE433489T1 (de) 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen
WO2002048361A3 (en) Novel secreted proteins and their uses
WO2001075076A3 (en) 33167, a novel human hydrolase and uses therefor
WO2001066764A3 (en) 16835, a human phospholipase c and uses thereof
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2
WO2002029042A3 (en) 48120, 23479, and 46689, novel human hydrolases and uses thereof
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
WO2002024898A3 (en) 47647, a human lipase and uses therefor
WO2002016569A3 (en) 38618, a human alpha/beta hydrolase and uses thereof
WO2001090146A3 (en) 57256 and 58289, human transporters and uses thereof
WO2002006485A3 (en) 47885, a novel human ubiquitin-activating enzyme and uses therefor
WO2000043514A3 (en) Human acid sensing ion channel and uses thereof
WO2001079293A3 (en) Human cadherin molecules and uses therefor
WO2001042286A3 (en) Human leucine rich repeat-containing polypeptide and uses therefor
WO2002057457A3 (en) Human proteins 55562 and 21617, and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties